ADDITION OF CETUXIMAB TO OXALIPLATIN-BASED COMBINATION CHEMOTHERAPY (CT) IN PATIENTS WITH K-ras WILD-TYPE ADVANCED COLORECTAL CANCER (ACRC): EFFECTS ON OVERALL SURVIVAL. MRC COIN (CR10) TRIAL RESULTS

Bibliografiset tiedot
Päätekijät:	Adams, R, Maughan, T, Smith, C, Seymour, M, Wilson, R, Meade, A, Fisher, D, Madi, A, Kenny, S, Wasan, H, Rogers, P, Hodgkinson, E, Jasani, B, Cheadle, J, Kaplan, R
Aineistotyyppi:	Journal article
Julkaistu:	2009

Addition of cetuximab to oxaliplatin-based combination chemotherapy (CT) in patients with KRAS wild-type advanced colorectal cancer (ACRC): a randomised superiority trial (MRC COIN)
Tekijä: Maughan, T, et al.
Julkaistu: (2009)

Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience.
Tekijä: Adams, R, et al.
Julkaistu: (2009)

THROMBOCYTOSIS AS A PREDICTIVE AND PROGNOSTIC MARKER IN ADVANCED COLORECTAL CANCER (ACRC): RESULTS OF THE MRC COIN TRIAL EXPLORED
Tekijä: Maughan, T, et al.
Julkaistu: (2010)

THE ADDITION OF CETUXIMAB TO OXALIPLATIN-FLUOROPYRIMIDINE CHEMOTHERAPY IN FIRST-LINE ADVANCED COLORECTAL CANCER IN THE MRC COIN TRIAL: IDENTIFICATION OF POTENTIALLY RESPONSIVE SUBSETS OF PATIENTS
Tekijä: Maughan, T, et al.
Julkaistu: (2010)

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial.
Tekijä: Madi, A, et al.
Julkaistu: (2012)

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: The MRC COIN trial
Tekijä: Madi, A, et al.
Julkaistu: (2012)

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
Tekijä: Maughan, T, et al.
Julkaistu: (2011)

THE IMPACT OF MILD RENAL IMPAIRMENT ON THE TOXICITY OF OXALIPLATIN AND FLUOROPYRIMIDINE REGIMENS: EXPERIENCE IN THE MRC COIN TRIAL
Tekijä: Madi, A, et al.
Julkaistu: (2010)

Intermittent Chemotherapy (CT) Plus Continuous or Intermittent Cetuximab (C) in the First-line Treatment of Advanced Colorectal Cancer (aCRC): Results of the Two-arm Phase II Randomised MRC COIN-B Trial
Tekijä: Wasan, H, et al.
Julkaistu: (2011)

Intermittent versus continuous oxaliplatin-based combination chemotherapy in patients with advanced colorectal cancer: a randomised non-inferiority trial (MRC COIN)
Tekijä: Adams, R, et al.
Julkaistu: (2009)

INTERMITTENT VS. CONTINUOUS OXALIPLATIN-FLUOROPYRIMIDINE CHEMOTHERAPY IN THE MRC COIN TRIAL IN ADVANCED COLORECTAL CANCER: UPDATED EFFICACY RESULTS, QUALITY OF LIFE AND POTENTIAL PREDICTIVE FACTORS
Tekijä: Adams, R, et al.
Julkaistu: (2010)

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
Tekijä: Adams, R, et al.
Julkaistu: (2011)

Cetuximab therapy in first-line metastatic colorectal cancer and intermittent palliative chemotherapy: review of the COIN trial.
Tekijä: Adams, R, et al.
Julkaistu: (2008)

A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS (RCTS) OF EGFR-TARGETED MONOCLONAL ANTIBODY (MAB) THERAPY IN ADVANCED COLORECTAL CANCER (ACRC): IMPACT OF K-RAS STATUS
Tekijä: Vale, C, et al.
Julkaistu: (2009)

Impact of K-ras status on the effects of EGFR-targeted monoclonal antibody (MAb) therapy in advanced colorectal cancer (ACRC): A systematic review and meta-analysis of randomized controlled trials (RCTs)
Tekijä: Vale, C, et al.
Julkaistu: (2009)

HIGH THROUGHPUT SOMATIC PROFILING OF THE RAS-RAF-MAP AND PI3K-PTEN-AKT PATHWAYS IN ADVANCED COLORECTAL CANCER AND CORRELATIONS WITH RESPONSE TO CETUXIMAB
Tekijä: Smith, C, et al.
Julkaistu: (2010)

CETUXIMAB COMBINED WITH INFUSIONAL 5-FLUOROURACIL/FOLINIC ACID AND OXALIPLATIN IN METASTATIC COLORECTAL CANCER: POOLED ANALYSIS OF COIN AND OPUS STUDY DATA
Tekijä: Taieb, J, et al.
Julkaistu: (2012)

Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer according to RAS and BRAF status: a post-hoc analysis of the MRC COIN study.
Tekijä: Wood, G, et al.
Julkaistu: (2017)

Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab.
Tekijä: Smith, C, et al.
Julkaistu: (2013)

Comprehensive pharmacogenetic profiling of the epidermal growth factor receptor pathway for biomarkers of response to, and toxicity from, cetuximab
Tekijä: Madi, A, et al.
Julkaistu: (2017)

Chemotherapy choices and doses in frail and elderly patients with advanced colorectal cancer: an MRC randomised clinical trial (FOCUS2)
Tekijä: Seymour, M, et al.
Julkaistu: (2007)

Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin
Tekijä: Elli Narvi, et al.
Julkaistu: (2018-11-01)

FOCUS4-D: Results from a randomised, placebo controlled trial (RCT) of AZD8931 (an inhibitor of signalling by HER1, 2, and 3) in patients (pts) with advanced or metastatic colorectal cancer (aCRC) in tumours that are wildtype (wt) for BRAF, PIK3CA, KRAS and NRAS
Tekijä: Adams, R, et al.
Julkaistu: (2016)

Design and development of information portal for Asian Communication Resource Centre (ACRC).
Tekijä: Yohanes Ramli.
Julkaistu: (2008)

Role for nucleotide-excision repair gene variants in oxaliplatin-induced peripheral neuropathy
Tekijä: West, H, et al.
Julkaistu: (2018)

Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial.
Tekijä: Seymour, M, et al.
Julkaistu: (2011)

Cost-Effectiveness Analysis of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) versus FOLFOX-4 in Patients with RAS Wild-Type Metastatic Colorectal Cancer
Tekijä: Bai L, et al.
Julkaistu: (2019-12-01)

Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy
Tekijä: Madi, A, et al.
Julkaistu: (2018)

Intra-tumoral Heterogeneity of KRAS and BRAF Mutation Status in Patients with Advanced Colorectal Cancer (aCRC) and Cost-Effectiveness of Multiple Sample Testing
Tekijä: Susan D. Richman, et al.
Julkaistu: (2011-01-01)

Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.
Tekijä: Seymour, M, et al.
Julkaistu: (2007)

MRC2020: improvements to Ximdisp and the MRC image-processing programs
Tekijä: J. M. Short, et al.
Julkaistu: (2023-09-01)

Oxaliplatin-Loaded Chitosan Nanoparticles Decorated with Cetuximab Single-Chain Variable Fragment for Human Colorectal Cancer Treatment
Tekijä: Khadijeh Falahzadeh, et al.
Julkaistu: (2024-09-01)

Combination Chemotherapy of Azacitidine and Cetuximab for Therapy-Related Acute Myeloid Leukemia following Oxaliplatin for Metastatic Colorectal Cancer
Tekijä: Akari Hashimoto, et al.
Julkaistu: (2014-05-01)

Cetuximab plus Irinotecan as third line chemotherapy for metastatic colorectal cancer
Tekijä: Moe, M, et al.
Julkaistu: (2008)

Chemotherapy-free intervals for patients with metastatic colorectal cancer remain an option.
Tekijä: Maughan, T, et al.
Julkaistu: (2010)

Pattern recognition receptor polymorphisms as predictors of oxaliplatin benefit in colorectal cancer
Tekijä: Gray, V, et al.
Julkaistu: (2019)

Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer.
Tekijä: John Pradeep Veluchamy, et al.
Julkaistu: (2016-01-01)

Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers
Tekijä: Wing-Lok Chan, et al.
Julkaistu: (2014-01-01)

A NOVEL COLORECTAL CANCER SUSCEPTIBILITY SNP IN THE EIF3H PROMOTER INFLUENCES PATIENT SURVIVAL AND RESPONSE TO TREATMENT
Tekijä: Cheadle, J, et al.
Julkaistu: (2010)

RAS and BRAF mutations in cell‐free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue‐tested RAS wild‐type advanced colorectal cancer
Tekijä: Erik J. vanHelden, et al.
Julkaistu: (2019-11-01)

ADDITION OF CETUXIMAB TO OXALIPLATIN-BASED COMBINATION CHEMOTHERAPY (CT) IN PATIENTS WITH K-ras WILD-TYPE ADVANCED COLORECTAL CANCER (ACRC): EFFECTS ON OVERALL SURVIVAL. MRC COIN (CR10) TRIAL RESULTS

Samankaltaisia teoksia

Samankaltaisia teoksia